Biophytis (EPA:ALBPS) | Finanzwire

Basculer en Français

9815	Companies
196879	Keywords
127951	Articles
104707	Press releases

Home
Companies
Biophytis

PRESS RELEASE

published on 06/12/2024 at 10:11, 1 year 7 months ago

Biophytis announces the successful industrial transfer of BIO101 (20-hydroxyecdysone) production by its service provider Seqens
Biophytis successfully transfers BIO101 (20-hydroxyecdysone) production to industrial scale with Seqens, enhancing therapeutic solutions for Duchenne Muscular Dystrophy patients

Biophytis Duchenne Muscular Dystrophy BIO101 Seqens 20-hydroxyecdysone
BRIEF

published on 06/12/2024 at 07:05, 1 year 7 months ago

Biophytis Announces Successful Industrial Transfer of BIO101 Production by Seqens

Biophytis Clinical Trial Duchenne Muscular Dystrophy BIO101 Seqens
REGULATED PRESS RELEASE

published on 06/12/2024 at 07:00, 1 year 7 months ago

Biophytis announces the successful industrial transfer of BIO101 (20-hydroxyecdysone) production by its service provider Seqens
Biophytis announces successful industrial transfer of BIO101 (20-hydroxyecdysone) production by Seqens for DMD treatment. Collaboration strengthens therapeutic solutions and accelerates clinical programs

Biophytis Clinical Development Duchenne Muscular Dystrophy BIO101 Seqens
BRIEF

published on 06/10/2024 at 08:23, 1 year 7 months ago

Biophytis Files IND Application for Phase 2 Obesity Study with US FDA

FDA Biophytis Clinical Study Obesity IND Application
BRIEF

published on 06/10/2024 at 08:21, 1 year 7 months ago

Biophytis files IND application for phase 2 study in obesity

FDA Biophytis Phase 2 BIO101 Obesity
REGULATED PRESS RELEASE

published on 06/10/2024 at 08:18, 1 year 7 months ago

Biophytis announces filing of an IND application with the US FDA for its phase 2 study in obesity
Biophytis files IND application with US FDA for phase 2 obesity study with BIO101 (20-hydroxyecdysone) to assess muscle strength improvement in lower limbs and secondary endpoints like mobility and body composition

FDA Biophytis BIO101 IND Application Obesity Study
PRESS RELEASE

published on 06/10/2024 at 08:16, 1 year 7 months ago

Biophytis announces filing of an IND application with the US FDA for its phase 2 study in obesity
Biophytis submits IND application to US FDA for phase 2 obesity study with BIO101 (20-hydroxyecdysone). Study to assess muscle strength & body composition. Research led by Professor Marc-André Cornier

Biophytis BIO101 IND Application Obesity Study Professor Marc-André Cornier
BRIEF

published on 06/07/2024 at 08:28, 1 year 7 months ago

Biophytis Announces Combined General Meeting on June 24, 2024

Shareholders Biophytis General Meeting Voting Agenda
REGULATED PRESS RELEASE

published on 06/07/2024 at 08:23, 1 year 7 months ago

Combined General Meeting of June 24, 2024
Biophytis SA to hold Combined General Meeting (CGM) on June 24, 2024 in Paris. Shareholders encouraged to vote in advance via multiple methods. Details available on the company's website

Shareholders Voting Combined General Meeting Biophytis SA CGM
BRIEF

published on 06/07/2024 at 07:44, 1 year 7 months ago

Biophytis Combined General Meeting scheduled for June 24, 2024

Shareholders Biophytis Paris General Assembly Vote

Accesswire

Published on 02/05/2026 at 18:50, 2 hours 10 minutes ago

Athena Gold Provides Exploration Update From Nevada and Ontario
Published on 02/05/2026 at 17:35, 3 hours 25 minutes ago

Pentagon I Capital Corp. Enters into Letter Agreement to Complete Qualifying Transaction with Prospectiva Resources Ltd.
Published on 02/05/2026 at 16:40, 4 hours 20 minutes ago

Relevant Gold Appoints Larry Taddei to Board of Directors and Mal Karwowska as Strategic Advisor
Published on 02/05/2026 at 15:45, 5 hours 15 minutes ago

American Critical Minerals Recaps a Highly Successful 6 Months and Files Amended and Restated Technical Report
Published on 02/05/2026 at 15:10, 5 hours 50 minutes ago

Electric Metals (USA) Limited Announces Change of Auditor

View all ACCESSWIRE

EQS Group

Published on 02/05/2026 at 19:27, 1 hour 32 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 02/05/2026 at 18:46, 2 hours 13 minutes ago

EQS-Adhoc: Mayr-Melnhof Karton AG: Impairment requirements impact profit for the financial year 2025
Published on 02/05/2026 at 18:09, 2 hours 50 minutes ago

Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 02/05/2026 at 17:55, 3 hours 4 minutes ago

Piramal Critical Care and Blue-Zone Technologies collaborate to capture, collect and recycle waste anaesthesia gas
Published on 02/05/2026 at 17:05, 3 hours 54 minutes ago

European Research and Innovation: the Politecnico di Milano Launches an Office in Brussels

Les Echos

Published on 02/05/2026 at 19:24, 1 hour 35 minutes ago

Minutes of the Combined General Meeting
Published on 02/05/2026 at 18:24, 2 hours 35 minutes ago

LNA SANTE : 2025 annual sales
Published on 02/05/2026 at 18:06, 2 hours 53 minutes ago

Aéroports de Paris SA - Shares and voting rights as of 31 January 2026
Published on 02/05/2026 at 18:00, 3 hours ago

Information concerning the total number of voting rights and shares in the share capital as of January 30, 2026
Published on 02/05/2026 at 18:00, 3 hours ago

ACM - Press release 2025 results

View all LES ECHOS COMFI WIRE